These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 6895577)

  • 21. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration.
    Tam CS; Heersche JN; Murray TM; Parsons JA
    Endocrinology; 1982 Feb; 110(2):506-12. PubMed ID: 7056211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats.
    Hock JM; Fonseca J; Gunness-Hey M; Kemp BE; Martin TJ
    Endocrinology; 1989 Oct; 125(4):2022-7. PubMed ID: 2791976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
    Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
    J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.
    Podbesek R; Edouard C; Meunier PJ; Parsons JA; Reeve J; Stevenson RW; Zanelli JM
    Endocrinology; 1983 Mar; 112(3):1000-6. PubMed ID: 6822201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6).
    Duque G; Macoritto M; Dion N; Ste-Marie LG; Kremer R
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E723-30. PubMed ID: 15572658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TSH prevents bone resorption and with calcitriol synergistically stimulates bone formation in rats with low levels of calciotropic hormones.
    Dumic-Cule I; Draca N; Luetic AT; Jezek D; Rogic D; Grgurevic L; Vukicevic S
    Horm Metab Res; 2014 May; 46(5):305-12. PubMed ID: 24446158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol.
    Felsenfeld AJ; Gutman RA; Drezner M; Llach F
    Miner Electrolyte Metab; 1986; 12(5-6):333-41. PubMed ID: 3543636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of intermittent administration of human PTH on experimental osteopenia in adult rat: a histomorphometric study of both trabecular and cortical bone of the vertebrae].
    Narita Y
    Nihon Seikeigeka Gakkai Zasshi; 1995 Oct; 69(10):1027-36. PubMed ID: 8551088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
    Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
    J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.
    Marie PJ; Hott M; Garba MT
    Calcif Tissue Int; 1985 May; 37(3):268-75. PubMed ID: 3926276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
    Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
    Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential regulation of insulin-like growth factor-I (IGF-I) and IGF-II release from cultured neonatal mouse calvaria by parathyroid hormone, transforming growth factor-beta, and 1,25-dihydroxyvitamin D3.
    Linkhart TA; Keffer MJ
    Endocrinology; 1991 Mar; 128(3):1511-8. PubMed ID: 1999170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice.
    Ono T; Tanaka H; Yamate T; Nagai Y; Nakamura T; Seino Y
    Endocrinology; 1996 Jun; 137(6):2633-7. PubMed ID: 8641218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
    Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
    J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid hormone sensitizes long bones to the stimulation of bone resorption by 1,25-dihydroxyvitamin D3.
    van Leeuwen JP; Birkenhäger JC; Bos MP; van der Bemd GJ; Herrmann-Erlee MP; Pols HA
    J Bone Miner Res; 1992 Mar; 7(3):303-9. PubMed ID: 1585831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro.
    Hara K; Akiyama Y; Tajima T; Shiraki M
    J Bone Miner Res; 1993 May; 8(5):535-42. PubMed ID: 8511981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.
    Hodsman AB; Kisiel M; Adachi JD; Fraher LJ; Watson PH
    Bone; 2000 Aug; 27(2):311-8. PubMed ID: 10913928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
    Leloup G; Lemoine P; Carmeliet P; Vaes G
    J Bone Miner Res; 1996 Aug; 11(8):1146-57. PubMed ID: 8854251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.